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The Parkinson disease phenotype (PDP) is a
complex trait resulting from the interaction
of multiple risk factors. The clearest risk fac-
tors in humans are genetic with autosomal
dominant and recessive forms contributing
to familial subtypes, but polymorphisms in
other genes may contribute to the sporadic
subtype (Cookson et al. 2005; Farrer 2006;
Feany 2004; Ross and Farrer 2005).
Nongenetic contributions to risk include
lifestyle, diet, age, and exposures to xeno-
biotics (Chen et al. 2005; Firestone et al.
2005; Gorell et al. 2004; Logroscino 2005;
Priyadarshi et al. 2001; Tanner 2003).
Different classes of compounds including
pesticides and metals have been implicated.
1-Methyl 4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP) is one xenobiotic producing a
form of the PDP that differs from the typical
sporadic form in speed of onset, systemic
administration, and lack of Lewy body for-
mation (Forno et al. 1993). Paraquat (PQ,
1,1´-dimethyl-4,4´-bipyridinium) is a pesti-
cide, dessicant, and defoliant and may be the
only specific xenobiotic implicated in the
sporadic human form of the PDP (Dinis-
Olivera et al. 2006). Human epidemiologic
data implicating PQ include individual case
reports and case–control studies (Liou et al.
1997; Sanchez-Ramos et al. 1987). Proving
a xenobiotic is a risk factor for the PDP in
humans is difficult because of challenges
associated with documenting and measuring
exposures from conception through diagno-
sis and the potentially long interval between
the exposure and the disease onset.
Paraquat was first produced commer-
cially as a pesticide in 1961 (Pesticide Action
Network United Kingdom 2007). Although
banned in several countries because of acute
toxicity, it remains one of the most widely
used pesticides in the world including the
United States and remains in use on more
than 100 crops. For example, nearly 1 mil-
lion pounds of PQ were used on an exten-
sive range of crops in 2005 in California
alone, reﬂecting an increase in use from pre-
vious years (California Department of
Pesticide Regulation 2005). PQ is one of the
most common workplace exposure risks in
Costa Rica (Partanen et al. 2003) and by
drift of aerial applications can affect nearby
individuals (Ames et al. 1993). The risk ver-
sus benefit for paraquat use is complex.
Evaluation must weigh the beneficial effect
of PQ on plant productivity versus its yet
unproven adverse effect in the human brain.
However, evaluating potential brain effects
in humans is difﬁcult and must rely initially
on animal studies.
Experimental animal data using PQ is
easier to obtain than human data and
exposure to PQ results in rodent models of
the PDP that are compelling. PQ has been
demonstrated to preferentially kill dopamin-
ergic neurons in the substantia nigra pars
compacta (SNpc) in mice in different labora-
tories (DiMonte et al. 2001; Dinis-Olivera
et al. 2006; Manning-Bog et al. 2003;
Thiruchelvam et al. 2000, 2003). It also pro-
duces dopamine (DA)-mediated behavioral
and biochemical changes in mice and rats
(Barlow et al. 2004; Corasaniti et al. 1991;
Ossawska et al. 2005; Thiruchelvam et al.
2005). The effects of PQ may occur after as
few as two relatively low (10 mg/kg) doses
(McCormack et al. 2005). It is active after
both injected and oral routes (Widdowson
et al. 1996). Although the reason for prefer-
ential dopaminergic neuron loss in models is
not known, a role for oxidative stress has
been strongly suggested based on in vitro
and in vivo evidence (McCormack et al.
2005; Yumino et al. 2002).
In performing toxicokinetics (TK) stud-
ies of PQ in different strains of mice, it
became clear that previous data from the
brain we collected might be incomplete
because of too short a sampling interval lim-
ited to 12 hr (Barlow et al. 2003). Presently,
multiple long-term studies (weeks) were per-
formed and demonstrate that the half-life of
PQ in brain is much longer. Additionally,
oral ingestion resulted in brain accumulation
similar to ip exposure. Because the oxidative
consequences of PQ are well established and
may contribute adverse effects, lipid peroxi-
dation and 20S proteasome functional activ-
ity were also determined. These data suggest
that the adverse effects associated with PQ
exposure in humans may be more complex
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BACKGROUND: Paraquat (PQ) has been implicated as a risk factor for the Parkinson disease pheno-
type (PDP) in humans and mice using epidemiologic or experimental approaches. The toxicokinet-
ics (TK) and toxicodynamics (TD) of PQ in the brain are not well understood.
OBJECTIVES: The TK and TD of PQ in brain were measured after single or repeated doses.
METHODS: Brain regions were analyzed for PQ levels, amount of lipid peroxidation, and functional
activity of the 20S proteasome.
RESULTS: Paraquat (10 mg/kg, ip) was found to be persistent in mouse ventral midbrain (VM) with
an apparent half-life of approximately 28 days and was cumulative with a linear pattern between
one and ﬁve doses. PQ was also absorbed orally with a concentration in brain rising linearly after
single doses between 10 and 50 mg/kg. The level of tissue lipid peroxides (LPO) was differentially
elevated in three regions, being highest in VM, lower in striatum (STR), and least in frontal cortex
(FCtx), with the earliest signiﬁcant elevation detected at 1 day. An elevated level of LPO was still
present in VM after 28 days. Despite the cumulative tissue levels of PQ after one, three, and ﬁve
doses, the level of LPO was not further increased. The activity of the 20S proteasome in the stria-
tum was altered after a single dose and reduced after ﬁve doses.
CONCLUSIONS: These data have implications for PQ as a risk factor in humans and in rodent models
of the PDP.
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disease, proteolytic stress, toxicodynamics, toxicokinetics, ubiquitin-proteasome system. Environ
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[Online 20 July 2007]than suspected because of the prolonged
retention in brain. PQ continues to serve as a
useful compound for modeling the PDP in
rodents and understanding mechanisms of
neurotoxicity.
Methods
Treatment and tissue acquisition. C57BL/6J
mice were bred, group housed in a climate-
and light-controlled (12/12-hr light/dark,
light on at 0600) room at the University of
Medicine and Dentistry of New Jersey
(UMDNJ). Food and water were provided
ad libitum. Male mice between 8 and
12 weeks of age were used, with a sample size
of four for each condition and time point.
Animals were treated humanely and with
regard for alleviation of suffering, and all
procedures were approved by the UMDNJ
Institutional Animal Care and Use
Committee (IACUC) and were in accor-
dance with the National Institutes of Health
Guide for the Care and Use of Laboratory
Animals (Clark et al. 1996). Paraquat (Sigma
Chemical Co., St. Louis, MO) was made
fresh in saline for each injection. PQ was
either injected by the ip route (10 mg/kg) or
administered orally by gavage (10–50 mg/kg).
The dose of 10 mg/kg is similar to what we
and others have used in adult mice
(McCormack et al. 2005). The same and
higher oral doses were used because of an
expected lower brain PQ level with that
route of exposure. When mice were treated
for more than one dose, a Monday–
Wednesday–Friday (M-W-F) regimen was
used. Mice given multiple doses were given
the same dose (10 mg/kg) at the approximate
same time of day. The dose was always based
on the animal’s current weight. Mice were
allowed to survive after administration for
1 hr to 28 days. Mice that were perfused
were anesthetized with Nembutal at a dose
of approximately 75 µg/g (~ 1.9 mg/25 g
mouse). Nembutal was diluted to 5 g/mL in
saline and a typical volume of 0.375 mL
used. After adequate anesthesia, mice were
perfused with cold isotonic saline (20 mL)
before sacriﬁce when the tissue was used for
paraquat determination. Mice were sacriﬁced
by cervical dislocation for all other outcome
measures. Brains were harvested, dissected on
ice to obtain the regions of interest including
frontal cortex (FCtx), striatum (STR), and
ventral midbrain (VM) containing the sub-
stantia nigra (SN), and immediately frozen
with dry ice. Tissues were stored at –80°C
until used in assays described below.
Paraquat determination. Tissue samples
(10–15 mg accurately weighed) placed into a
1.5-mL centrifuge tube were mixed with
150 µL of 12% acetic acid and then soni-
cated for approximately 20 min. The cen-
trifuge tubes were placed in high-pressure
microwaveable Teflon extraction vessels
(CEM HP500; CEM Corp., Matthews, NC)
and heated in a microwave digestion/extrac-
tion system (CEM MARS; CEM Corp.) for
30 min at 50% power. The samples were
then centrifuged using a 10-kDa filter
(Nanosep 10k Omega Pall Trincor; Omega
Pall Corp., Exton, PA) and the ﬁltrate trans-
ferred to HPLC/autosample vials and stored
at –30°C until analysis. The PQ separation
was carried out on ZORBAX RX-C8,
4.6 mm × 15 cm, 5-µm column (Agilent
Technologies, Santa Clara, CA) with reverse-
phase column guard 4.3 mm × 1 cm. PQ was
eluted at ﬂow rate 0.3 mL/min with a reten-
tion time of 5 min monitored by both ultra-
violet detector and mass spectrometer
(Waters 996 photodiode array detector;
Waters Corp., Milford, MA). A 50-µL sam-
ple was injected. Gradient elution was estab-
lished with three-solvent system (Table 1):
0.1% formic acid in water (A), 0.1% formic
acid in methanol (B), and 0.1% formic acid
in acetonitrile (C). Each calibration curve
was prepared separately for each experiment
and composed of PQ standards (Sigma
Chemicals) with a concentration range of
0–12 ng. As a part of each experiment matrix
blanks and spikes were prepared. Matrix
blanks were prepared by adding 150 µl of the
extraction solvent to untreated mouse brain
tissue. The linear range was 0–2 ng/µL.
Quantiﬁcation was carried out using an LCQ
ion trap mass spectrometer (Finnigan, San
Jose, CA) equipped with an electrospray ion-
ization source (ESI) and operated using
Xcalibur 1.3 software (ThermoFischer
Scientiﬁc Waltham, MA). Quantiﬁcation of
PQ was based on integrated peak areas of the
m/z 186 ion in selective ion monitoring
(SIM) mode with isolation width m/z 1.
Lipid hydroperoxide assay. Frozen tissue
samples were quickly homogenized in 10 mM
Tris–HCl buffer (pH 7.4) with a tissue sample
weight to volume of 1:20 and an equal volume
of ExtractR (LPO Assay Kit; Calbiochem, San
Diego, CA) saturated with deoxygenated
methanol was added. After vortexing, 2 vol of
cold deoxygenated chloroform was added and
after additional vortexing, the mixture was
centrifuged at 1,500 × g for 5 min at 4°C. The
bottom chloroform layer was collected and
used for the lipid peroxides measurements.
The assay measures lipid hydroperoxides
directly using redox reactions with ferrous
ions. The resulting ferric ions were detected
using thiocyanate as a chromogen by measur-
ing absorbance at 500 nm. Hydroperoxide val-
ues in samples were calculated using the
equation obtained from the linear regression of
a standard curve and finally adjusted to the
protein content in each sample.
Proteasome activity. Tissue samples were
sonicated at a setting of 25 (range 0–100,
Branson Sonifier 250 (Branson Ultrasonics,
Danbury, CT) for 10 sec in 50 mM Hepes,
pH 7.5, 150 mM NaCl, 5 mM EDTA, and
1% Triton X-100 in the presence of protease
inhibitors (leupeptin 0.5 µg/mL, aprotinin
1.0 µg/mL, pepstatin A 0.7 µg/mL, and
antipain 50 µg/mL) at a weight to volume of
20:1. Samples were spun at 14,000 rpm for
15 min at 4°C with removal of the super-
natant to a new tube. The protein concentra-
tions were determined and samples diluted to
3 µg/µL before use. Black flat-bottom
microtiter plates were filled in order with
incubation buffer (50 mM Tris–HCl,
pH 7.5; tissue supernatant, 5 µL), and sub-
strates (5 µL) to a ﬁnal volume of 200 µL on
ice. Samples were run in duplicate or tripli-
cate. Control tissue in the absence or presence
of the inhibitor MG-132 (100 µM) was also
analyzed. Plates were analyzed using a Tecan
Genios (Tecan US, Durham, NC) plate
reader at 37°C using an excitation filter
(360 nm), an emission filter (465 nm), a
manual gain of 60, 3 ﬂashes per reading, with
measurements performed every 2 min for a
total of 60 min with shaking between each
reading. Suc-Leu-Leu-Val-Tyr-AMC (20 µM,
Boston Biochem, Boston, MA) was used to
determine the chymotrypsin-like (ChymT-
like) activity and Z-Leu-Leu-Glu-AMC
(80 µM; Boston Biochem) was used to deter-
mine peptidylglutamyl peptide hydrolyzing
(PGPH) activity. An increasing linear curve
was observed after a short delay for all tissue
samples for the 60-min duration. Specific
activity was determined by subtracting activity
from wells containing MG-132 (100 µM).
Protein concentrations were determined once
more after dilutions, and those values used for
the ﬁnal calculation of activity in units of rela-
tive ﬂuorescence units (RFU) per microgram
protein per hour.
Statistical analysis. Levels of PQ in toxi-
cokinetic studies, concentration of lipid per-
oxides, and proteasomal activity were
analyzed using two-factor analysis of vari-
ances (ANOVAs) with either treatment and
time point or treatment and number of doses
as between group factors. Post hoc assess-
ments were carried out based on main effects
or interactions as appropriate. For all analy-
ses, p-values of ≤ 0.05 were considered statis-
tically signiﬁcant.
Toxicokinetics and toxicodynamics of paraquat
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Table 1. Gradient elution for three solvent systems
for HPLC.
Time Flow Solvent system (%)
(min) (mL/min) A B C
0.00 0.3 60 25 15
5.00 0.3 50 25 25
6.00 0.3 30 25 45
15.00 0.3 30 25 45
16.00 0.3 60 25 15
20.00 0.3 60 25 15Results
The ventral midbrain (VM) was used as the
primary region for PQ measurement because
it is the primary region with cell loss in
Parkinson disease and previous data from our
laboratory demonstrated that other brain
regions (striatum, frontal cortex, and cerebel-
lum) had similar levels of PQ 12 hr after
administration (Barlow et al. 2003). In previ-
ous TK studies, radioactive PQ was used,
whereas a safer and more sensitive liquid
chromatography–mass spectrometry assay has
been developed and used in this study.
Clarifying the TK we performed five inde-
pendent time-course studies of differing dura-
tion in the C57BL/6J strain (Figure 1). These
studies support existing data indicating only a
fraction of the systemic dose enters into the
brain compared with the liver (Figure 1B)
(Barlow et al. 2003). PQ was persistent in
brain with failure to demonstrate complete
elimination even after 4 weeks (Figure 1A).
There was greater variation in PQ concentra-
tions at early time points (< 3 days) compared
with later time points (> 3 days). When the
longest time course was plotted using a log
scale, the elimination appeared linear, with a
brain half-life of approximately 4 weeks (r2 =
0.76). The PQ detected throughout the time
course was unchanged in structure, with no
breakdown products being detected. It is
unclear whether the slow decline in brain was
due to metabolism of PQ to an undetected
metabolite or the very slow elimination of
native PQ.
We then sought to understand the bio-
logical effects of repeated doses of PQ in
brain. The same dose (10 mg/kg) was
administered ip 3 times/week (M-W-F) for a
total of one, three, or five doses (Figure 2).
There was a linear increase in PQ in the VM
(r2 = 0.99). When administered orally (10,
20, or 50 mg/kg) a similar linear increase in
PQ levels was observed in the VM following
an increasing dose (r2 = 1.00; Figure 3).
Treating a separate group of mice using
similar time points and doses, we measured
the tissue level of lipid peroxides (LPO) and
the functional activity of the 20S proteasome
as toxicodynamic (TD) responses to PQ. We
measured LPO levels in three regions. The
level of LPO after a single ip dose
(10 mg/kg) was increased in as short a time
as 1 hr (although not signiﬁcantly) and per-
sisted for up to 28 days. The overall
ANOVA for a single dose measured in three
regions at four time points was significant
(F4,15 = 24.9 p < 0.0001) with a signiﬁcant
effect for region (F2,15 = 61.0 p < 0.0001)
and an interaction of region with time point
(F8,30 = 3.0, p = 0.013). (Figure 4A).
Maximal effects occurred between 1 and
7 days. Effects were highest in VM, lower in
the STR, and least in FCtx. Interestingly,
repeated dosing did not result in an increase
in the amount of LPO (Figure 4B). Multiple
doses of PQ signiﬁcantly increased the level
of LPO in each region (region ANOVAs:
VM, F3,12 = 9.9, p = 0.001; STR, F3,12 =
17.9, p < 0.0001; FCtx, F3,12 = 3.8, p =
0.04) when measured after 1 week compared
with saline.
The ChymT-like and PGPH activities of
the 20S proteasome were measured using
the remaining piece of striatal tissue and
were acutely elevated at 1 and 24 hr after
a single ip dose of PQ in the STR
(Figure 5A). This effect was not present 7 or
28 days after a single dose. There was a sig-
niﬁcant overall effect of PQ on ChymT-like
activity (F4,22 = 9.6, p < 0.001) compared
with saline with a significant increase in
activity seen after 1 and 24 hr (post hoc
p-values < 0.003). There was a similar sig-
nificant overall effect of PQ on PGPH
activity (F4,22 = 3.9, p = 0.016) compared
with saline, but the post hoc tests did not
reveal a significant increase after 1 and
24 hr, although a trend was present (post
hoc p-values < 0.12). The variances were
greater for the PGPH activity compared
with the ChymT-like activity and sample
sizes were quite small (n = 4). Multiple
doses of PQ resulted in a signiﬁcant overall
effect of PQ on ChymT-like (F3,20 = 4.1,
p < 0.02) activity compared with saline,
with a significant decrease in activity seen
after five doses (post hoc p = 0.029).
Multiple doses of PQ did not result in a
significant overall effect of PQ on PGPH
Prasad et al.
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Figure 1. Time course of PQ in ventral midbrain (VM) and liver. (A) Brain values for PQ. (B) Brain and liver
values for PQ. PQ (10 mg/kg) was injected by the ip route and tissue harvested at different time points. A
total of ﬁve independent time–course studies were performed with each time point from each study hav-
ing sample size of four as indicated by a mean and SE for a total of 72 mice. Each type of symbol repre-
sents an independent experiment. Values in the VM (A) had greater variability at early time points (1 hr–
3 days) compared with later time points (4 day–4 weeks). A plot of the log PQ concentration versus time
(using the data from the experiment with the longest time point, ﬁlled squares) suggests a roughly linear
decrease (r2 = 0.76, linear regression with 95% conﬁdence interval) with a brain half-life of about 4 weeks
(A). At no time point was PQ entirely eliminated from brain in contrast to liver (open square) where elimi-
nation was complete at 4 days (B; all other symbols represent VM from A). Levels in the liver (and other
organs) are much higher than those in brain.
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Figure 2. Effect of repeated doses of PQ. PQ
(10 mg/kg) was administered ip for a total of one,
three (M-W-F), or five (M-W-F-M-W) doses and
measured one week after the last dose in the VM.
There was a linear increase in the amount of PQ
(r2 = 0.99) with the number of doses (linear fit and
95% conﬁdence interval). Each value represents a
mean ± SE from four mice.
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Figure 3. Effect of oral administration of PQ. PQ
was administered once at each of three doses (10,
20, and 50 mg/kg po) and assayed after 4 and 6 hr.
As similar values were found at both time points
only the 6-hr data are presented. There was a lin-
ear relationship between dose and level in the VM
(r2 = 1.0, 95% confidence intervals) using the 6-hr
time point. Each value represents a mean ± SE
from four mice.
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20 30 40 50activity (F3,19 = 3.4, p = 0.07) compared
with saline although there was a trend with
the direction and magnitude of change simi-
lar to those seen with ChymT-like activity.
Repeated doses resulted in no significant
effects after one or three doses, but ﬁve doses
significantly decreased ChymT-like activity
7 days after treatment (Figure 5B).
Discussion
This study demonstrates that PQ persists in
the VM of mice for a prolonged time, with a
half-life of approximately one month. The
reason for this persistence in brain in con-
trast to that in other organs is not known,
but this persistence may contribute to its
prolonged adverse effects. PQ elimination in
laboratory animals and humans from blood
and organs other than the brain has always
been reported in hours and days (Dey et al.
1990; Houze et al. 1990). It is unclear if the
slow loss of PQ from the VM was due to
metabolism, export, or both. The TK of PQ
in brain has not been well studied due to its
low concentration and technical demands of
the available assays. The long half-life of the
charged PQ was surprising. Our previous
report using [14C]-PQ failed to demonstrate
complete excretion but was limited to a
12-hr duration (Barlow et al. 2003).
Additional data supported this prolonged
half-life. PQ was linearly cumulative in VM
between one, three, and ﬁve doses, support-
ing the lack of elimination between doses.
Given a half-life of approximately 28 days in
mouse brain, the accumulation of PQ with
repeated exposure would be expected. If this
TK pattern applies to humans, repeated
exposures may be more adverse than sus-
pected and the limits to exposure may need
to be reconsidered. Given the prolonged
duration of PQ in brain, adverse effects
should be evaluated in terms of cumulative
brain concentration and duration of expo-
sure rather than dose, number of doses, or
interval between doses.
Other studies using radiolabeled PQ
found that it was absorbed by all exposure
routes tested, including intravenous, intra-
gastric, dermal, and pulmonary (Chui et al.
1988; Dey et al. 1990). PQ in brain after
oral dosing was previously demonstrated in
rat and the concentration was higher after
10 doses compared with 1, supporting its
accumulation (Widdowson et al. 1996).
Thus, oral, dermal, and inhalational expo-
sures to PQ are all feasible as in models and
relevant to human exposure. Given this long
half-life and accumulation of PQ in mouse
brain and the potential for all routes of expo-
sure to contribute, this information should
be considered in evaluating the human risk
associated with PQ.
Despite low brain PQ concentrations,
adverse effects in vivo are clearly based on
multiple measures performed by us and oth-
ers including the loss of DA neurons, alter-
ations in DA level and metabolism in the
striatum, and changes in oxidative status
using different species of rodents (Di Monte
et al. 2001; Fredriksson et al. 1993;
Gonzalez-Polo et al. 2004; Hara et al.
1991; Manning-Bog et al. 2002, 2003;
McCormack et al. 2002, 2005; Miranda-
Contreras et al. 2005; Ossawska et al. 2005;
Shimizu et al. 2003; Thiruchelvam et al.
2000a, 2000b, 2002, 2003, 2005). This arti-
cle demonstrated prolonged elevated oxida-
tive stress after a single exposure, with brain
PQ levels between 0.1 and 0.2 ng/mg tissue.
Based on published work by others we can
extrapolate that brain concentrations near
0.3 ng/mg tissue (following a minimum of
two 10-mg/kg doses) result in neuronal
death in the SN of mice (McCormack et al.
2005). Although the mechanism(s) for the
adverse effects of PQ on dopaminergic neu-
rons is incompletely understood, oxidative
stress (a well-known consequence of PQ) or
other processes are likely to play a role
(Andersen 2004).
Our data on the level of lipid peroxida-
tion conﬁrmed signiﬁcant elevation of reac-
tive oxygen species (ROS) after single and
repeated doses of PQ (McCormack et al.
2005; Thiruchelvam et al. 2005; Yang and
Sun 1998; Yang and Tiffany-Castiglioni
2005; Yumino et al. 2002). The lack of dif-
ference between one, three, and ﬁve doses of
PQ on LPO levels might suggest a ceiling
effect due to a limited number of targets or a
tissue compensatory response to the induced
stress over time. We expect that ROS formed
would cause irreversible oxidative damage to
proteins. Moderately carbonylated proteins
undergo degradation by the ubiquitin/pro-
teasome pathway (UPS) (Poppek and Grune
2006), which might explain the temporal
activation of proteasomal activity at 1 and
24 hr in striatum after a single dose of PQ.
Toxicokinetics and toxicodynamics of paraquat
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Figure 4. Levels of lipid peroxidation (LPO) in three brain regions after PQ exposure. The level of LPO was
measured in VM, striatum (STR), and frontal cortex (FCtx) after different durations of exposure to (A) a sin-
gle dose of PQ (10 mg/kg) or (B) 1 week after a total of one, three (M-W-F), or ﬁve (M-W-F-M-W) doses of
PQ (10 mg/kg). Greatest effects were identiﬁed in the VM, lesser in STR, and least in FCtx, as previously
reported for a single 24-hr time point. Signiﬁcant effects were present at 24 hr and 7 days in all regions but
were still present up to 28 days in VM. The level of LPO was not signiﬁcantly increased between one and
ﬁve doses of PQ. However, each region demonstrated signiﬁcantly elevated LPO with VM > STR > FCtx.
Each value represents a mean ± SE from four mice.
(A) *Signiﬁcantly different from saline for respective region, all post hoc p < 0.005. (B) *Signiﬁcantly different from saline
for respective region, all post hoc p < 0.026). 
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Figure 5. Functional proteasome activity in STR following PQ. The activity of the 20S proteasome was mea-
sured in the STR after different durations of exposure to a single dose of PQ (10 mg/kg) (A) or 1 week after
a total of one, three (M-W-F), or ﬁve (M-W-F-M-W) doses of PQ (10 mg/kg) (B) in mice also analyzed for
LPO levels using other tissue samples (Figure 4). An assay for the chymotrypsin-like activity (ChymT-like)
and the peptidylglutamyl peptide hydrolyzing activity (PGPH) of the 20S proteasome were run. Each value
represents a mean ± SE from four mice. 
*Signiﬁcantly different from saline with all post hoc p < 0.03.
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*Sublethal proteasome inhibition induces
neurons to increase proteasome activity and
promotes resistance to oxidative injury (Lee
et al. 2004), whereas oxidative stress can
increase proteasome activity early in the
sequence leading to cell death in vitro (Holtz
2006). Interestingly, PQ has been shown to
produce intracellular protein aggregation in
neurons after repeated dosing, although the
mechanism is unknown (Manning-Bog et al.
2002). Excessive generation of oxidative
stress alone may damage proteasomes
directly (Farout 2006) and certain pesticides
are known to directly inhibit proteasomal
activity (Wang et al. 2006).
The TK and TD of PQ in brain are due
to the interaction of genetic and environ-
mental factors. Environmental factors
include diet, nutritional status, exposure to
other xenobiotics, age, and potentially many
other factors. Given that PQ may not be
metabolized in brain and the intact molecule
may be solely responsible for adverse effects,
the TK in brain may be related to a limited
number of proteins participating in the bi-
directional transport into and out of the
brain and cells. Transporters thought to con-
tribute include the amino acid transporters
for crossing the blood–brain barrier
(McCormack and Di Monte 2003; Shimizu
and Ohtaki. 2001). Transporters involved in
cellular and subcellular transport have not
been clearly established but may include
organic cation transporters (Jack et al. 2000;
Smith 1982; Sokol et al. 1987; Wu et al.
1998). The use of different inbred or recom-
binant inbred mouse strains will be useful for
identifying the mechanisms and genes partic-
ipating in the TK and TD of PQ. Those
mechanisms and genes may then be exam-
ined in relationship to PQ vulnerability
in humans.
Conclusions
The TK and TD of paraquat are complex.
The accumulation and persistence of PQ in
brain suggest the human exposure limits to
PQ might need to be reconsidered. Models
of the PDP using PQ should be evaluated in
terms of total brain accumulation and dura-
tion of exposure rather than number and
frequency of doses.
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